Cero Therapeutics Holdings Inc. Announces $7 Million Private Placement of Series E Convertible Preferred Stock

Reuters
Oct 14
Cero <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Holdings Inc. Announces $7 Million Private Placement of Series E Convertible Preferred Stock

Cero Therapeutics Holdings Inc. has announced a private placement, entering into a Securities Purchase Agreement with certain accredited investors for the sale of up to 9,750 shares of its Series E convertible preferred stock, raising up to $7 million in total. Approximately $1.8 million will be funded at the first closing, with additional closings subject to mutual agreement and customary conditions. As part of the agreement, holders of the company's outstanding Series C and Series D convertible preferred stock have consented to the issuance of the Series E shares on a pari passu basis, in exchange for a reduction in the conversion price of their shares to $1.76. The Series E preferred stock holders will also receive purchase rights if the company issues similar rights to common stockholders in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-098421), on October 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10